PHARMANUTRA SPA (PHN.MI) Fundamental Analysis & Valuation

BIT:PHN • IT0005274094

Current stock price

80.5 EUR
+1.8 (+2.29%)
Last:

This PHN.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. PHN.MI Profitability Analysis

1.1 Basic Checks

  • PHN had positive earnings in the past year.
  • In the past year PHN had a positive cash flow from operations.
  • PHN had positive earnings in each of the past 5 years.
  • In the past 5 years PHN always reported a positive cash flow from operatings.
PHN.MI Yearly Net Income VS EBIT VS OCF VS FCFPHN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

1.2 Ratios

  • PHN's Return On Assets of 20.17% is amongst the best of the industry. PHN outperforms 100.00% of its industry peers.
  • PHN's Return On Equity of 36.55% is amongst the best of the industry. PHN outperforms 86.67% of its industry peers.
  • With an excellent Return On Invested Capital value of 25.72%, PHN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for PHN is significantly above the industry average of 11.61%.
  • The 3 year average ROIC (17.21%) for PHN is below the current ROIC(25.72%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 20.17%
ROE 36.55%
ROIC 25.72%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
PHN.MI Yearly ROA, ROE, ROICPHN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1.3 Margins

  • With a decent Profit Margin value of 13.39%, PHN is doing good in the industry, outperforming 66.67% of the companies in the same industry.
  • In the last couple of years the Profit Margin of PHN has declined.
  • The Operating Margin of PHN (21.79%) is better than 100.00% of its industry peers.
  • In the last couple of years the Operating Margin of PHN has remained more or less at the same level.
  • PHN's Gross Margin of 97.13% is amongst the best of the industry. PHN outperforms 100.00% of its industry peers.
  • In the last couple of years the Gross Margin of PHN has remained more or less at the same level.
Industry RankSector Rank
OM 21.79%
PM (TTM) 13.39%
GM 97.13%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
PHN.MI Yearly Profit, Operating, Gross MarginsPHN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. PHN.MI Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PHN is creating value.
  • PHN has about the same amout of shares outstanding than it did 1 year ago.
  • PHN has less shares outstanding than it did 5 years ago.
  • PHN has a better debt/assets ratio than last year.
PHN.MI Yearly Shares OutstandingPHN.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
PHN.MI Yearly Total Debt VS Total AssetsPHN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • PHN has an Altman-Z score of 12.30. This indicates that PHN is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of PHN (12.30) is better than 100.00% of its industry peers.
  • The Debt to FCF ratio of PHN is 2.01, which is a good value as it means it would take PHN, 2.01 years of fcf income to pay off all of its debts.
  • With a decent Debt to FCF ratio value of 2.01, PHN is doing good in the industry, outperforming 66.67% of the companies in the same industry.
  • A Debt/Equity ratio of 0.24 indicates that PHN is not too dependend on debt financing.
  • With a decent Debt to Equity ratio value of 0.24, PHN is doing good in the industry, outperforming 73.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF 2.01
Altman-Z 12.3
ROIC/WACC3.27
WACC7.86%
PHN.MI Yearly LT Debt VS Equity VS FCFPHN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

  • PHN has a Current Ratio of 2.19. This indicates that PHN is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.19, PHN belongs to the top of the industry, outperforming 93.33% of the companies in the same industry.
  • PHN has a Quick Ratio of 1.86. This is a normal value and indicates that PHN is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.86, PHN belongs to the top of the industry, outperforming 93.33% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 1.86
PHN.MI Yearly Current Assets VS Current LiabilitesPHN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. PHN.MI Growth Analysis

3.1 Past

  • The earnings per share for PHN have decreased strongly by -14.74% in the last year.
  • The Earnings Per Share has been growing by 8.59% on average over the past years. This is quite good.
  • PHN shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.13%.
  • The Revenue has been growing by 16.51% on average over the past years. This is quite good.
EPS 1Y (TTM)-14.74%
EPS 3Y-2.81%
EPS 5Y8.59%
EPS Q2Q%N/A
Revenue 1Y (TTM)21.13%
Revenue growth 3Y21.08%
Revenue growth 5Y16.51%
Sales Q2Q%-37.6%

3.2 Future

  • PHN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.45% yearly.
  • The Revenue is expected to grow by 15.31% on average over the next years. This is quite good.
EPS Next Y43.02%
EPS Next 2Y23.44%
EPS Next 3Y24.48%
EPS Next 5Y21.45%
Revenue Next Year15.93%
Revenue Next 2Y15.61%
Revenue Next 3Y15.33%
Revenue Next 5Y15.31%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
PHN.MI Yearly Revenue VS EstimatesPHN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 50M 100M 150M 200M 250M
PHN.MI Yearly EPS VS EstimatesPHN.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

2

4. PHN.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • PHN is valuated quite expensively with a Price/Earnings ratio of 60.53.
  • Compared to the rest of the industry, the Price/Earnings ratio of PHN indicates a rather expensive valuation: PHN more expensive than 80.00% of the companies listed in the same industry.
  • PHN is valuated expensively when we compare the Price/Earnings ratio to 27.15, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 39.72, which means the current valuation is very expensive for PHN.
  • Based on the Price/Forward Earnings ratio, PHN is valued more expensive than 86.67% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of PHN to the average of the S&P500 Index (22.12), we can say PHN is valued expensively.
Industry RankSector Rank
PE 60.53
Fwd PE 39.72
PHN.MI Price Earnings VS Forward Price EarningsPHN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PHN is valued more expensive than 80.00% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, PHN is valued more expensive than 93.33% of the companies in the same industry.
Industry RankSector Rank
P/FCF 74.75
EV/EBITDA 17.57
PHN.MI Per share dataPHN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • PHN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • PHN has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as PHN's earnings are expected to grow with 24.48% in the coming years.
PEG (NY)1.41
PEG (5Y)7.05
EPS Next 2Y23.44%
EPS Next 3Y24.48%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. PHN.MI Dividend Analysis

5.1 Amount

  • PHN has a Yearly Dividend Yield of 1.26%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 2.58, PHN's dividend is way lower than its industry peers. On top of this 80.00% of the companies listed in the same industry pay a better dividend than PHN!
  • PHN's Dividend Yield is slightly below the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 1.26%

5.2 History

  • On average, the dividend of PHN grows each year by 11.21%, which is quite nice.
Dividend Growth(5Y)11.21%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • PHN pays out 39.70% of its income as dividend. This is a sustainable payout ratio.
  • PHN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP39.7%
EPS Next 2Y23.44%
EPS Next 3Y24.48%
PHN.MI Yearly Income VS Free CF VS DividendPHN.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M
PHN.MI Dividend Payout.PHN.MI Dividend Payout, showing the Payout Ratio.PHN.MI Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

PHN.MI Fundamentals: All Metrics, Ratios and Statistics

PHARMANUTRA SPA

BIT:PHN (4/28/2026, 11:25:14 AM)

80.5

+1.8 (+2.29%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)03-17
Earnings (Next)05-11
Inst Owners15.13%
Inst Owner ChangeN/A
Ins Owners65.02%
Ins Owner ChangeN/A
Market Cap779.24M
Revenue(TTM)100.20M
Net Income(TTM)24.16M
Analysts82.86
Price Target88.74 (10.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.26%
Yearly Dividend0.85
Dividend Growth(5Y)11.21%
DP39.7%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.67%
PT rev (3m)7.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.43%
Valuation
Industry RankSector Rank
PE 60.53
Fwd PE 39.72
P/S 4.32
P/FCF 74.75
P/OCF 53.93
P/B 11.79
P/tB 18.68
EV/EBITDA 17.57
EPS(TTM)1.33
EY1.65%
EPS(NY)2.03
Fwd EY2.52%
FCF(TTM)1.08
FCFY1.34%
OCF(TTM)1.49
OCFY1.85%
SpS18.64
BVpS6.83
TBVpS4.31
PEG (NY)1.41
PEG (5Y)7.05
Graham Number14.2949 (-82.24%)
Profitability
Industry RankSector Rank
ROA 20.17%
ROE 36.55%
ROCE 44.34%
ROIC 25.72%
ROICexc 34.17%
ROICexgc 53.82%
OM 21.79%
PM (TTM) 13.39%
GM 97.13%
FCFM 5.78%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
ROICexc(3y)25.61%
ROICexc(5y)33.67%
ROICexgc(3y)43.23%
ROICexgc(5y)50.61%
ROCE(3y)29.76%
ROCE(5y)31.61%
ROICexgc growth 3Y-15.98%
ROICexgc growth 5Y-10.26%
ROICexc growth 3Y-20.69%
ROICexc growth 5Y-11.75%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
F-Score7
Asset Turnover1.51
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF 2.01
Debt/EBITDA 0.37
Cap/Depr 112.59%
Cap/Sales 2.23%
Interest Coverage 250
Cash Conversion 33.69%
Profit Quality 43.15%
Current Ratio 2.19
Quick Ratio 1.86
Altman-Z 12.3
F-Score7
WACC7.86%
ROIC/WACC3.27
Cap/Depr(3y)763.09%
Cap/Depr(5y)544.05%
Cap/Sales(3y)14.97%
Cap/Sales(5y)11.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.74%
EPS 3Y-2.81%
EPS 5Y8.59%
EPS Q2Q%N/A
EPS Next Y43.02%
EPS Next 2Y23.44%
EPS Next 3Y24.48%
EPS Next 5Y21.45%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y21.08%
Revenue growth 5Y16.51%
Sales Q2Q%-37.6%
Revenue Next Year15.93%
Revenue Next 2Y15.61%
Revenue Next 3Y15.33%
Revenue Next 5Y15.31%
EBIT growth 1Y10.97%
EBIT growth 3Y13.47%
EBIT growth 5Y17.77%
EBIT Next Year22.37%
EBIT Next 3Y20.22%
EBIT Next 5Y14.04%
FCF growth 1Y164.53%
FCF growth 3Y1.75%
FCF growth 5Y17.94%
OCF growth 1Y18.84%
OCF growth 3Y0.14%
OCF growth 5Y11.34%

PHARMANUTRA SPA / PHN.MI Fundamental Analysis FAQ

What is the fundamental rating for PHN stock?

ChartMill assigns a fundamental rating of 7 / 10 to PHN.MI.


What is the valuation status of PHARMANUTRA SPA (PHN.MI) stock?

ChartMill assigns a valuation rating of 2 / 10 to PHARMANUTRA SPA (PHN.MI). This can be considered as Overvalued.


Can you provide the profitability details for PHARMANUTRA SPA?

PHARMANUTRA SPA (PHN.MI) has a profitability rating of 8 / 10.


Can you provide the financial health for PHN stock?

The financial health rating of PHARMANUTRA SPA (PHN.MI) is 8 / 10.


Can you provide the expected EPS growth for PHN stock?

The Earnings per Share (EPS) of PHARMANUTRA SPA (PHN.MI) is expected to grow by 43.02% in the next year.